Andere talen Rigel Pharmaceuticals, Inc.

Aandelen

RIGL

US7665596034

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,1 ^USD	0,00%		+1,85%	-24,14%

12/03	Rigel Pharmaceuticals kondigt benoeming aan van Lisa Rojkjaer als Chief Medical Officer	CI
07/03	RIGEL PHARMACEUTICALS, INC. : Citigroup herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Rigel Pharmaceuticals : March 2024	16/04
Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement	12/04
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	10/04
Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia and Lymphoma	05/04
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer	12/03
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	12/03
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M	05/03
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS	28/02
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update	27/02
Rigel Pharmaceuticals Seeks Acquisitions	11/01
Rigel Pharmaceuticals Provides Business Update	09/01
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	05/01
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise	04/01
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma	04/01
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma	04/01
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML and Other Cancers	11/12
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications	08/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Rigel Pharmaceuticals, Inc.

Aandelen

RIGL

US7665596034

Andere talen

Filters